{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-017458","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.840627+00:00","generated_at":"2026-05-26T23:12:54.107890+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Cytokinetics appoints Robert E. Landry to Board of Directors, effective Feb 10, 2025","bullets":["Robert E. Landry appointed as Class II director, term expiring at 2027 annual meeting.","Also appointed to Audit Committee; Board determined independent under SEC and Nasdaq rules.","Compensation includes $50k annual retainer, $12.5k Audit Committee retainer, and annual equity grant of $440k.","Received initial option grant of 25,538 shares with $700k grant date fair value, vesting over three years.","Standard indemnification agreement entered into; no other arrangements or transactions requiring disclosure."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-017458","json":"https://secwatch.observer/filing/0000950170-25-017458.json","markdown":"https://secwatch.observer/filing/0000950170-25-017458.md","text":"https://secwatch.observer/filing/0000950170-25-017458.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/0000950170-25-017458-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/cytk-20250210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:12:54.107890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a7ffe8f79","claim":"Robert E. Landry was appointed as Director at CYTOKINETICS INC.","evidence_excerpt":"On February 10, 2025, (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Cytokinetics, Incorporated (the “ Company ”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert E. Landry to fill a vacant Board seat and to serve as a Class II member of the Board with an initial term expiring at the Company’s 2027 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/0000950170-25-017458-index.htm","confidence":1.0}],"comparable_filings":[{"accession":"0001213900-26-063573","ticker":"MZYX","company_name":"MOZAYYX Acquisition Corp.","filed_at":"2026-06-01T21:00:14+00:00","headline":"MOZAYYX Acquisition appoints Emma Rose Bienvenu as independent director","event_type":"leadership","sec_items":["5.02"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063573","json":"https://secwatch.observer/filing/0001213900-26-063573.json","markdown":"https://secwatch.observer/filing/0001213900-26-063573.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2097376/000121390026063573/0001213900-26-063573-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2097376/000121390026063573/ea0292919-8k_moxayyx.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 10, 2025, (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Cytokinetics, Incorporated (the “ Company ”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert E. Landry to fill a vacant Board seat and to serve as a Class II member of the Board with an initial term expiring at the Company’s 2027 annual meeting of stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/0000950170-25-017458-index.htm","comparable_excerpt":"On May 26, 2026, the Board of Directors (the “ Board ”) of MOZAYYX Acquisition Corp. (the “ Company ”) appointed Emma Rose Bienvenu to serve as an independent director of the Company, effective immediately.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2097376/000121390026063573/0001213900-26-063573-index.htm"}},{"accession":"0001477932-26-003559","ticker":"JOB","company_name":"GEE Group Inc.","filed_at":"2026-06-01T20:47:44+00:00","headline":"Darla Moore resigns from GEE Group board effective June 1, 2026, due to other commitments","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.35,"calibrated_materiality_score":0.35,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-003559","json":"https://secwatch.observer/filing/0001477932-26-003559.json","markdown":"https://secwatch.observer/filing/0001477932-26-003559.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/40570/000147793226003559/0001477932-26-003559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/40570/000147793226003559/job_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 10, 2025, (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Cytokinetics, Incorporated (the “ Company ”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert E. Landry to fill a vacant Board seat and to serve as a Class II member of the Board with an initial term expiring at the Company’s 2027 annual meeting of stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/0000950170-25-017458-index.htm","comparable_excerpt":"On June 1, 2026, GEE Group Inc. (the “Company”) (NYSE American: JOB) issued a press release announcing that Ms. Darla Moore, has resigned as a member of the Board of Directors (the “Board”) and from all committees of the Company’s Board effective June 1, 2026, due to the time requirements necessary for her existing and new business commitments.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/40570/000147793226003559/0001477932-26-003559-index.htm"}},{"accession":"0001534969-26-000028","ticker":"SERA","company_name":"SERA PROGNOSTICS, INC.","filed_at":"2026-06-01T20:44:21+00:00","headline":"Sera Prognostics director Jeff Elliott resigns ahead of annual meeting","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001534969-26-000028","json":"https://secwatch.observer/filing/0001534969-26-000028.json","markdown":"https://secwatch.observer/filing/0001534969-26-000028.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534969/000153496926000028/0001534969-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534969/000153496926000028/sera-20260526.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 10, 2025, (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Cytokinetics, Incorporated (the “ Company ”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert E. Landry to fill a vacant Board seat and to serve as a Class II member of the Board with an initial term expiring at the Company’s 2027 annual meeting of stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/0000950170-25-017458-index.htm","comparable_excerpt":"Jeffrey T. Elliott, a member of the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”), notified the Company of his decision to resign from the Board effective as of June 4, 2026","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1534969/000153496926000028/0001534969-26-000028-index.htm"}},{"accession":"0001681459-26-000035","ticker":"FTI","company_name":"TechnipFMC plc","filed_at":"2026-06-01T20:38:05+00:00","headline":"TechnipFMC appoints Eric D. Mullins to Board of Directors effective June 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.25,"calibrated_materiality_score":0.25,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001681459-26-000035","json":"https://secwatch.observer/filing/0001681459-26-000035.json","markdown":"https://secwatch.observer/filing/0001681459-26-000035.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681459/000168145926000035/0001681459-26-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681459/000168145926000035/fti-20260529.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 10, 2025, (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Cytokinetics, Incorporated (the “ Company ”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert E. Landry to fill a vacant Board seat and to serve as a Class II member of the Board with an initial term expiring at the Company’s 2027 annual meeting of stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/0000950170-25-017458-index.htm","comparable_excerpt":"the Board elected Eric Mullins to the Board and appointed Mr. Mullins to the Audit Committee of the Board, effective June 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1681459/000168145926000035/0001681459-26-000035-index.htm"}},{"accession":"0001193125-26-251548","ticker":"MCRB","company_name":"Seres Therapeutics, Inc.","filed_at":"2026-06-01T20:30:55+00:00","headline":"Seres Therapeutics board member Hans-Juergen Woerle resigns, effective May 31, 2026","event_type":"leadership","sec_items":["5.02"],"materiality_score":0.25,"calibrated_materiality_score":0.25,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251548","json":"https://secwatch.observer/filing/0001193125-26-251548.json","markdown":"https://secwatch.observer/filing/0001193125-26-251548.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526251548/0001193125-26-251548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526251548/d100982d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 10, 2025, (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Cytokinetics, Incorporated (the “ Company ”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert E. Landry to fill a vacant Board seat and to serve as a Class II member of the Board with an initial term expiring at the Company’s 2027 annual meeting of stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/0000950170-25-017458-index.htm","comparable_excerpt":"On May 30, 2026, Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a member of the board of directors of Seres Therapeutics, Inc. (the “Company”) and on the committees on which he serves, effective May 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526251548/0001193125-26-251548-index.htm"}},{"accession":"0000827054-26-000020","ticker":"MCHP","company_name":"MICROCHIP TECHNOLOGY INC","filed_at":"2026-06-01T20:18:43+00:00","headline":"Microchip appoints former SVP Mitch Little to board, effective June 1, 2026","event_type":"leadership","sec_items":["5.02"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000827054-26-000020","json":"https://secwatch.observer/filing/0000827054-26-000020.json","markdown":"https://secwatch.observer/filing/0000827054-26-000020.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/827054/000082705426000020/0000827054-26-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/827054/000082705426000020/mchp-20260528.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 10, 2025, (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Cytokinetics, Incorporated (the “ Company ”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert E. Landry to fill a vacant Board seat and to serve as a Class II member of the Board with an initial term expiring at the Company’s 2027 annual meeting of stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/0000950170-25-017458-index.htm","comparable_excerpt":"appointed Mitch Little, former Senior Vice President, Worldwide Client Engagement of Microchip, as a member of the Board, effective June 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/827054/000082705426000020/0000827054-26-000020-index.htm"}},{"accession":"0001680247-26-000091","ticker":"PUMP","company_name":"ProPetro Holding Corp.","filed_at":"2026-06-01T20:16:36+00:00","headline":"Director Alex Volkov resigns from ProPetro board after Pioneer (Exxon) sells all shares","event_type":"leadership","sec_items":["5.02"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001680247-26-000091","json":"https://secwatch.observer/filing/0001680247-26-000091.json","markdown":"https://secwatch.observer/filing/0001680247-26-000091.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680247/000168024726000091/0001680247-26-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680247/000168024726000091/pump-20260528.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 10, 2025, (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Cytokinetics, Incorporated (the “ Company ”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert E. Landry to fill a vacant Board seat and to serve as a Class II member of the Board with an initial term expiring at the Company’s 2027 annual meeting of stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/0000950170-25-017458-index.htm","comparable_excerpt":"On May 28, 2026, ProPetro Holding Corp. (the “Company”) announced the resignation of Alex V. Volkov from the Company’s Board of Directors (the “Board”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1680247/000168024726000091/0001680247-26-000091-index.htm"}},{"accession":"0001104659-26-068930","ticker":"DE","company_name":"DEERE & CO","filed_at":"2026-06-01T20:15:26+00:00","headline":"Deere director Dmitri Stockton will not seek re-election at 2027 annual meeting","event_type":"leadership","sec_items":["5.02"],"materiality_score":0.25,"calibrated_materiality_score":0.25,"match_reasons":["same fact type: executive_change","same SEC item: 5.02","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068930","json":"https://secwatch.observer/filing/0001104659-26-068930.json","markdown":"https://secwatch.observer/filing/0001104659-26-068930.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/315189/000110465926068930/0001104659-26-068930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315189/000110465926068930/de-20260526x8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 10, 2025, (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Cytokinetics, Incorporated (the “ Company ”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert E. Landry to fill a vacant Board seat and to serve as a Class II member of the Board with an initial term expiring at the Company’s 2027 annual meeting of stockholders.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/0000950170-25-017458-index.htm","comparable_excerpt":"On May 26, 2026, Dmitri Stockton notified the Board of Directors (the “Board”) of Deere & Company (the “Company”) that he would not stand for re-election as a director at the 2027 annual meeting of stockholders.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/315189/000110465926068930/0001104659-26-068930-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}